BackJounce Therapeutics Overview

Jounce Therapeutics Receivables

Latest receivables for JNCE: $0.

Get informed when a big investor buys or sells

+ Follow
Receivables
$0.00

Peer trimmed avg / median

Loading

Jounce Therapeutics Receivables History

Loading

Jounce Therapeutics vs. peers: Receivables Comparison

Loading

Jounce Therapeutics Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Jounce Therapeutics (JNCE) FAQ

Jounce Therapeutics (JNCE) currently reports a receivables of $0 as of December 2022. In the prior-year period, the figure was $0. Use the charts on this page to explore Jounce Therapeutics's receivables history and peer comparisons.

Jounce Therapeutics's receivables changed from $0 to $0 (period ending December 2022). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Jounce Therapeutics reported $0 in receivables as of December 2022. In the prior-year period, the figure was $0. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current receivables of $0, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Jounce Therapeutics, and consider following JNCE for alerts when major investors trade the stock.

Jounce Therapeutics is classified in the Healthcare sector. On receivables, it currently shows $0. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing JNCE with unrelated industries.